Dan Ou1, Ingrid Garberis2, Julien Adam2, Pierre Blanchard3, France Nguyen3, Antonin Levy3, Odile Casiraghi2, Philippe Gorphe4, Ingrid Breuskin4, François Janot4, Stephane Temam4, Jean-Yves Scoazec2, Eric Deutsch3, Yungan Tao5. 1. Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 2. Department of Pathology, Gustave Roussy, Paris-Saclay University, Villejuif, France. 3. Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France. 4. Department of Head and Neck Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France. 5. Department of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France. Electronic address: yungan.tao@gustaveroussy.fr.
Abstract
BACKGROUND AND PURPOSE: The aim of the present study was to investigate the role of three hypoxia-related biomarkers in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with concurrent chemoradiotherapy (3-weekly cisplatin) or bioradiotherapy (weekly cetuximab). MATERIAL AND METHODS: In tumor tissue material from 100 patients with known HPV status, we evaluated the extent of tumor necrosis, the expression level of CA-IX and the microvascular density (MVD) measured as the density of CD34+ vascular structures. The correlations between biomarker expressions and clinicopathological characteristics and treatment outcomes were analyzed. RESULTS: We found a significant correlation of MVD with UICC stage (p = 0.02) and T classification (p = 0.05), of CA-IX with UICC stage (p = 0.03) and N classification (p = 0.04) and a significant inverse correlation of MVD with CA-IX expression (r = -0.22, p = 0.03). Multivariate analysis showed that low MVD combined with high CA IX-expression was a significant independent prognostic factor for worse loco-regional control (HR = 2.6, 95%CI 1.1-5.0, p = 0.02) in the whole population but not in the p16+ subgroup. Patients treated with CRT had a better LRC than those with BRT independent of MVD or CA-IX expression. CONCLUSIONS: The combination of MVD and CA-IX expression might give additional prognostic information in HNSCC patients with known HPV status.
BACKGROUND AND PURPOSE: The aim of the present study was to investigate the role of three hypoxia-related biomarkers in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with concurrent chemoradiotherapy (3-weekly cisplatin) or bioradiotherapy (weekly cetuximab). MATERIAL AND METHODS: In tumor tissue material from 100 patients with known HPV status, we evaluated the extent of tumor necrosis, the expression level of CA-IX and the microvascular density (MVD) measured as the density of CD34+ vascular structures. The correlations between biomarker expressions and clinicopathological characteristics and treatment outcomes were analyzed. RESULTS: We found a significant correlation of MVD with UICC stage (p = 0.02) and T classification (p = 0.05), of CA-IX with UICC stage (p = 0.03) and N classification (p = 0.04) and a significant inverse correlation of MVD with CA-IX expression (r = -0.22, p = 0.03). Multivariate analysis showed that low MVD combined with high CA IX-expression was a significant independent prognostic factor for worse loco-regional control (HR = 2.6, 95%CI 1.1-5.0, p = 0.02) in the whole population but not in the p16+ subgroup. Patients treated with CRT had a better LRC than those with BRT independent of MVD or CA-IX expression. CONCLUSIONS: The combination of MVD and CA-IX expression might give additional prognostic information in HNSCCpatients with known HPV status.
Authors: Eva-Leonne Göttgens; Christian Ostheimer; Paul N Span; Jan Bussink; Ester M Hammond Journal: Br J Radiol Date: 2018-03-14 Impact factor: 3.039
Authors: Nils H Nicolay; Nicole Wiedenmann; Michael Mix; Wolfgang A Weber; Martin Werner; Anca L Grosu; Gian Kayser Journal: Eur J Nucl Med Mol Imaging Date: 2019-12-07 Impact factor: 9.236
Authors: Claire Smalley Rumfield; Samuel T Pellom; Jeffrey Schlom; Caroline Jochems; Y Maurice Morillon Ii Journal: J Immunother Cancer Date: 2020-06 Impact factor: 13.751
Authors: Martin Dolezel; Marek Slavik; Tomas Blazek; Tomas Kazda; Pavel Koranda; Lucia Veverkova; Petr Burkon; Jakub Cvek Journal: J Pers Med Date: 2022-07-29